Can-Fite BioPharma (CANF) Registration filing summary

Company overview and business model

• Advanced clinical-stage biopharmaceutical company developing orally bioavailable small molecule therapeutics for cancer, liver, and inflammatory diseases, leveraging the A3 adenosine receptor (A3AR) as a therapeutic target.

• Pipeline includes CF101 (Piclidenoson) for psoriasis and Lowe syndrome, CF102 (Namodenoson) for HCC, MASH, and pancreatic cancer, and CF602 for erectile dysfunction.

• Out-licensing agreements for key drug candidates in multiple global territories; no commercial sales to date.

• Focus on global partnerships and out-licensing for commercialization, with no plans to develop in-house manufacturing or sales force.

Financial performance and metrics

• As of December 31, 2025, total capitalization was $6.8 million, with shareholders' equity of $5.6 million.

• Aggregate market value of outstanding equity held by non-affiliates was approximately $9.9 million as of July 1, 2026.

• Since inception, the company has incurred significant losses related to research and development.

Use of proceeds and capital allocation

• Net proceeds from offerings will be used for general corporate purposes, including working capital, R&D, regulatory affairs, clinical trials, acquisitions, and potential debt repayment.

• For the at-the-market offering, proceeds are specifically intended for funding research and development, clinical trials, and general corporate purposes.